JAMA Oncology

JAMA Oncology JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed publications.

Among adults with treatment-refractory, HER2-positive , zanidatamab produced sustained, meaningful clinical responses a...
11/22/2025

Among adults with treatment-refractory, HER2-positive , zanidatamab produced sustained, meaningful clinical responses and extended survival compared to prior standards.

In patients with immunohistochemistry (IHC) 3+ tumors, response rates and overall survival were notably higher than those with IHC 2+ tumors, substantiating the use of reflex IHC testing to identify candidates for HER2-targeted therapy.

Safety remained consistent over 33 months of follow-up, and the ongoing HERIZON-BTC-302 phase 3 trial is assessing zanidatamab alongside first-line standard care in this setting.

https://ja.ma/3XccBTN

Incorporating clinical comorbidity and MRI-based factors, the IMPACT tool accurately predicted disease progression risk,...
11/21/2025

Incorporating clinical comorbidity and MRI-based factors, the IMPACT tool accurately predicted disease progression risk, enabling clinicians to stratify patients into early intervention, serial monitoring, or discharge from outpatient care.

Individuals with high-risk meningiomas had a progression rate of approximately 50%, medium-risk 24%, and low-risk under 4%, supporting tailored clinical management pathways. https://ja.ma/4pmDzEk

Among patients undergoing active surveillance for favorable-risk , multiparametric alone demonstrated a negative pred...
11/20/2025

Among patients undergoing active surveillance for favorable-risk , multiparametric alone demonstrated a negative predictive value of 75% for ruling out grade group 2 or higher disease at confirmatory biopsy and 77% at surveillance biopsy.

MRI was most reliable among those with grade group 1 at diagnosis and lower PSA density, yet in no subgroup did NPV exceed 80%, except when PSA density was below 0.15 ng/mL during surveillance.

https://ja.ma/4oRE35y

Meta-analysis: Among patients with intermediate-, high-, or very high-risk prostate cancer, the ideal duration of ADT wi...
11/20/2025

Meta-analysis: Among patients with intermediate-, high-, or very high-risk prostate cancer, the ideal duration of ADT with radiotherapy demonstrated nonlinear benefits, with diminished gains after 12 months and variation in benefit by risk group. https://ja.ma/4pqkDoh

Among patients with advanced urothelial cancer, upfront enfortumab vedotin dose reduction was linked to a 50% reduction ...
11/15/2025

Among patients with advanced urothelial cancer, upfront enfortumab vedotin dose reduction was linked to a 50% reduction in treatment interruption risk but did not compromise overall survival. https://ja.ma/49eTdwN

This cross-disciplinary international position statement summarizes the current understanding of CV toxic effects associ...
11/14/2025

This cross-disciplinary international position statement summarizes the current understanding of CV toxic effects associated with ICI therapy, including strategies for diagnosis, treatment, and potential rechallenge and an outline of relevant knowledge gaps. https://ja.ma/43sqL6R

Among women under 50, those with the highest ultraprocessed food intake had 45% higher odds of early-onset colorectal co...
11/13/2025

Among women under 50, those with the highest ultraprocessed food intake had 45% higher odds of early-onset colorectal conventional adenomas versus those with the lowest intake; no significant association was seen for serrated lesions. https://ja.ma/47CnYKO

In a nonrandomized phase 2 trial of adults with advanced dMMR/MSI-H noncolorectal cancers, combined nivolumab/ipilimumab...
11/13/2025

In a nonrandomized phase 2 trial of adults with advanced dMMR/MSI-H noncolorectal cancers, combined nivolumab/ipilimumab showed an objective response rate of 63% and 6-month progression-free survival rate of 71%. https://ja.ma/49iXoru

A 78-year-old man with a history of nonmelanoma skin cancers presented with left-sided upper and lower facial weakness. ...
11/10/2025

A 78-year-old man with a history of nonmelanoma skin cancers presented with left-sided upper and lower facial weakness. What is your diagnosis? https://ja.ma/3XfiXlj

Rare pathogenic variants in 16 predisposition genes were linked to both single and multiple cancer diagnoses, suggesti...
11/09/2025

Rare pathogenic variants in 16 predisposition genes were linked to both single and multiple cancer diagnoses, suggesting multigene panel testing could be beneficial. https://ja.ma/47KnHEr

Semaglutide and tirzepatide prescriptions for obesity have increased among patients with preexisting cancer, with notabl...
11/08/2025

Semaglutide and tirzepatide prescriptions for obesity have increased among patients with preexisting cancer, with notable variation by cancer type and absence of cancer-specific guidelines. https://ja.ma/3LqYiZ6

AI technologies hold potential to enhance acute myeloid leukemia management by improving risk stratification, early dete...
11/07/2025

AI technologies hold potential to enhance acute myeloid leukemia management by improving risk stratification, early detection, and treatment optimization through integration of clinical, morphological, and genetic data. https://ja.ma/49D12fI

Address

330 N Wabash Avenue
Chicago, IL
60611

Telephone

+13126707827

Website

Alerts

Be the first to know and let us send you an email when JAMA Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category